CN106902107A - A kind of pharmaceutical composition for treating atherosclerosis and application - Google Patents
A kind of pharmaceutical composition for treating atherosclerosis and application Download PDFInfo
- Publication number
- CN106902107A CN106902107A CN201710070494.4A CN201710070494A CN106902107A CN 106902107 A CN106902107 A CN 106902107A CN 201710070494 A CN201710070494 A CN 201710070494A CN 106902107 A CN106902107 A CN 106902107A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- limonene
- irisone
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Abstract
The invention belongs to a kind of pharmaceutical composition for treating atherosclerosis and application；The pharmaceutical composition is formulated comprising following raw materials according：(+) limonene, γ irisones, ethylmaltol；Raised with Induced by High Fat Diet in Rats blood fat is substantially suppressed, can effectively treat atherosclerosis and effect is obvious, Quality Control stabilization is suitable to the advantage of patient's long-term taking.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition for treating atherosclerosis and should
With.
Background technology
Atherosclerosis is one kind of artery sclerosis, takes place mostly in big or middle endarterium, and occur containing cholesterol,
The yellow atheromatous plaque material of class fat etc., is caused by fat metabolic disturbance, neural blood vessel functional disturbance more.Often result in thrombus shape
Into, blood supply disorder etc..The morbidity crowd of atherosclerosis is more common in the male of more than 40 years old and the women after climacteric.This disease
It is often accompanied by hypertension, hypercholesterolemia or diabetes etc..Atherosclerosis is a kind of common disease, frequently-occurring disease, the death rate and
One of disability rate disease higher, the life and health of the mankind in serious harm, is common in brain worker, is also that the elderly causes
The one of the main reasons died of illness.
At present, not yet there is the medicine that preferably treatment atherosclerosis occurs and develops.Common prevention is rationally drinking
Eat, take exercises, take a good rest based on, but effect is undesirable.
The content of the invention
It is an object of the invention to overcome defect of the prior art, there is provided special quality control stabilization, safely and effectively, natural nothing
Poison and it is suitable to a kind of pharmaceutical composition for treating atherosclerosis of long-term taking and application.
The object of the present invention is achieved like this：The pharmaceutical composition is formulated comprising following raw materials according：(+)-limonene,
γ-irisone, ethylmaltol.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：- irisone 8-100 parts, ethylmaltol 10-100 parts of 1-100 parts of (+)-limonene, γ.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：- irisone 8-80 parts, ethylmaltol 10-80 parts of 1-80 parts of (+)-limonene, γ.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：- irisone 8-50 parts, ethylmaltol 10-50 parts of 1-50 parts of (+)-limonene, γ.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of (+)-limonene, 8 parts of γ-irisone, 15 parts of ethylmaltol.
The invention provides application of the aforementioned pharmaceutical compositions in the medicine for preparing treatment atherosclerosis.
(+) of the present invention-limonene, γ-irisone, ethylmaltol can directly pass through to be commercially available,
Can be obtained by plant extract.The present invention pulverizes and sieves above-mentioned raw materials respectively by weight, mixes, and loads capsule or pressure
It is made as tablet；Or mix with pharmaceutically acceptable carrier or diluent, reinstall capsule or be compressed to tablet.
Present invention also offers the instructions of taking of described pharmaceutical composition, its dose is in terms of said composition：Adult, 6~
8mg/ times, 3 times/day, you can reach the effect for the treatment of atherosclerosis clinical symptoms, particularly point out, the special population such as pregnant woman
Need to be followed the doctor's advice when taking, its special adverse reaction is not yet found at present.Treatment of the present invention means the treatment after morbidity, no
Represent the intervention of premorbid.
Heretofore described (+)-limonene, molecular formula is C10H16, molecular weight is 136.23, and molecular structural formula is：
γ-irisone, molecular formula is C13H20O, molecular weight is 192.30.Molecular structural formula is：
Ethylmaltol, molecular formula is C7H8O3, molecular weight is 140.14.Molecular structural formula is：
Find according to the study, (+)-limonene, γ-irisone, the composition of ethylmaltol composition can treat artery
Atherosis rat model serum cholesterol, triglycerides, low-density lipoprotein are raised, and treat atherosclerosis model rats
Artery plaque is formed, and treats atherosclerosis model rats Artery injury, and treatment atherosclerosis model rats are moved
Arteries and veins endothelial cell damage.
The present invention has found that artery is athero- by rat blood serum cholesterol, triglycerides, low-density lipoprotein assay
Hardening model rat blood serum cholesterol, triglycerides, low-density lipoprotein content are significantly raised, and pharmaceutical composition of the invention can
Raised with effectively treating atherosclerosis model rats serum cholesterol, triglycerides, low-density lipoprotein content.
The present invention is by visually observing discovery to rat chest aorta, and atherosclerosis model rats artery plaque is bright
Aobvious, pharmaceutical composition of the invention can effectively treat atherosclerotic rat artery plaque and be formed.
The present invention is by the discovery of rat chest aorta om observation, atherosclerosis model rats Artery injury
Substantially, pharmaceutical composition of the invention can effectively treat atherosclerotic rat Artery injury.
Heretofore described (+)-limonene, γ-irisone, ethylmaltol are extracted into both from natural drug
Point, compared with traditional Chinese medicine, have the advantages that quality controllable.Found by zoopery and clinical patients are on probation, the present invention
Raised with Induced by High Fat Diet in Rats blood fat is substantially suppressed, can effectively treat atherosclerosis and effect substantially, Quality Control stabilization and
It is suitable to the advantage of patient's long-term taking.
Brief description of the drawings
Fig. 1 is that pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence figure, (see by naked eyes
Examine).
Fig. 2 is pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence figure (light microscopic 400
×)。
Specific embodiment
The present invention is a kind of pharmaceutical composition for treating atherosclerosis and application, and the pharmaceutical composition includes following original
Material is formulated：(+)-limonene, γ-irisone, ethylmaltol.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：- irisone 8-100 parts, ethylmaltol 10-100 parts of 1-100 parts of (+)-limonene, γ.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：- irisone 8-80 parts, ethylmaltol 10-80 parts of 1-80 parts of (+)-limonene, γ.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：- irisone 8-50 parts, ethylmaltol 10-50 parts of 1-50 parts of (+)-limonene, γ.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of (+)-limonene, 8 parts of γ-irisone, 15 parts of ethylmaltol.
The invention provides application of the aforementioned pharmaceutical compositions in the medicine for preparing treatment atherosclerosis.
In order to more clearly explain the present invention, it is further described in conjunction with specific embodiment.It is specific real
Under applying for example：
Embodiment one
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：0.9 part of (+)-limonene, 7 parts of γ-irisone, 102 parts of ethylmaltol.
Embodiment two
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：101 parts of (+)-limonene, 7 parts of γ-irisone, 9 parts of ethylmaltol.
Embodiment three
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：102 parts of (+)-limonene, 101 parts of γ-irisone, 9 parts of ethylmaltol.
Example IV
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of (+)-limonene, 8 parts of γ-irisone, 10 parts of ethylmaltol.
Embodiment five
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：100 parts of (+)-limonene, 100 parts of γ-irisone, 100 parts of ethylmaltol.
Embodiment six
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：50.5 parts of (+)-limonene, 54 parts of γ-irisone, 55 parts of ethylmaltol.
Embodiment seven
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：80 parts of (+)-limonene, 44 parts of γ-irisone, 80 parts of ethylmaltol.
Embodiment eight
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：40.5 parts of (+)-limonene, 80 parts of γ-irisone, 45 parts of ethylmaltol.
Embodiment nine
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：25.5 parts of (+)-limonene, 50 parts of γ-irisone, 50 parts of ethylmaltol.
Embodiment ten
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：50 parts of (+)-limonene, 29 parts of γ-irisone, 30 parts of ethylmaltol.
Embodiment 11
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of (+)-limonene, 8 parts of γ-irisone, 15 parts of ethylmaltol.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and not to the restriction of implementation method.
For the general technical staff of art, the change of other multi-forms can also be made on the basis of the above description
Or change.There is no need and unable to be exhaustive to all of implementation method, and the obvious change thus amplified out
Or among changing still in the invention scope of the claims.
The present invention can be by being prepared into the medicine of various multi-forms to (+)-limonene, γ-irisone, ethylmaltol
Agent, such as：The forms such as aqueous solvent, powder and mixture；Medicine is weighed according to following weight when needing to prepare aqueous solvent, (+)-lemon
Alkene 1mg, γ-irisone 8mg, ethylmaltol 15mg, mix, are dissolved in tri-distilled water, packing.When needing to prepare powder
Medicine is weighed according to following weight, (+)-limonene 0.1g, γ-irisone 0.8g, ethylmaltol 1.5g, mixing, packing
.Medicine is weighed according to following deal when needing to prepare mixture, (+)-limonene 0.1g, γ-irisone 0.8g, ethyl
Maltol 1.5g, mixing, packing, filling capsule.
Test example：The detection present invention is to atherosclerosis model rats serum cholesterol, triglycerides, low-density lipoprotein
Bai Hanliang, aorta pectoralis naked eyes form, morphology.
1st, medicine：(+)-limonene, γ-irisone, ethylmaltol, Lovastatin have from Beijing cloud scientific research science and technology
Limit company purchases.
2nd, animal：Sprague-Dawley (SD) rat, 6 week old, male, 180~220g, cleaning grade, by Henan Province's reality
Animal center offer is provided.
3rd, experiment packet：Rat adapts to raise 1 week in laboratory, without exception in activity, feed, excrement, 40 rats
4 groups are randomly divided into by table of random number：(1) Normal group；(2) Atherosclerosis Model group；(3) Lovastatin group
(100mg/kg)；(4) of the present invention group (5mg/kg).
4th, experiment content：Rat blood serum cholesterol, triglycerides, low-density lipoprotein Content, aorta pectoralis is visually
Form, morphology.
5th, statistical method：All data are with mean ± standard deviationRepresent.Group difference compare with ANOVA and
Newman-Student Multiple range tests；T check analyses, are completed by the statistical softwares of SPSS 13.0, and bilateral P ＜ 0.05 think difference
There is conspicuousness.
6th, result
6.1 present invention are to atherosclerosis model rats serum cholesterol, triglycerides, low-density lipoprotein content
Influence：Result of the test shows that the rat blood serum cholesterol of Atherosclerosis Model group, triglycerides, low-density lipoprotein contain
Amount is significantly higher than Normal group (P ＜ 0.05), rat blood serum cholesterol, triglycerides, the low-density lipoprotein of present invention group
Content is substantially less than Atherosclerosis Model group (P ＜ 0.05).(the results are shown in Table 1)
Influence of the present invention of table 1 to atherosclerosis model rats blood fat
Note：* P ＜ 0.05, the #P ＜ 0.05 compared with Lovastatin group compared with Atherosclerosis Model group.
6.2 as shown in figure 1, for pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence
Figure (visually observing).As can be seen from the figure atherosclerosis model rats artery plaque is obvious, drug regimen of the invention
Thing can effectively treat atherosclerotic rat artery plaque and be formed.Normal group shown in Fig. 1 is 1；Artery is athero-
Hardening model group is 2；Lovastatin group is 3；Present invention group is 4.
6.3 as shown in Fig. 2 for pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence
Figure (light microscopic 400 ×).It can be seen that atherosclerosis model rats Artery injury is substantially, medicine of the invention
Compositions can effectively treat atherosclerotic rat Artery injury.Normal group shown in Fig. 2 is 1；It is dynamic
Pulse atherosclerosis model group is 2；Lovastatin group is 3；Present invention group is 4.
The form and feature of pharmaceutically acceptable carrier of the present invention or diluent are by by mixed activity
The amount of composition, method of administration, physiological disposition (including absorb, distribution, metabolism, excretion) and other known variable determined.
Necessarily " acceptable ", i.e., they should can be adapted to these carriers with other compositions of preparation, not interfere with the effect of said preparation
And it is not detrimental to the recipient of said preparation.For example, the pharmaceutical carriers for being used can be solid or liquid.Solid carrier
Example be lactose, carclazyte, sucrose, talcum powder, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, poly- second
Glycol, polyvinylpyrrolidone, collagen hydrolysate etc..The example of liquid-carrier is PBS, syrup, breast
Liquid, wetting agent, sterile solution etc..Similarly, carrier or diluent may include time delay material well known in the art, such as individually
Glycerin monostearate or distearin or the mixture with wax.Large-scale medicament forms can be used.Therefore, such as
Fruit uses solid carrier, and said preparation can be placed on hard gelatine capsule with piece agent, with powder or particle form, into lozenge or lozenge
Form.The change of the amount of solid carrier will be very big, but preferably about 50mg to about 1g.When using liquid-carrier, preparation can
In the form of into syrup, emulsion, soft gelatine capsule.
Claims (6)
1. a kind of pharmaceutical composition for treating atherosclerosis, it is characterised in that：The pharmaceutical composition is matched somebody with somebody comprising following raw materials according
System is formed：(+)-limonene, γ-irisone, ethylmaltol.
2. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：- irisone 8-100 parts of 1-100 parts of (+)-limonene, γ, second
10-100 parts of base maltol.
3. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：- irisone 8-80 parts of 1-80 parts of (+)-limonene, γ, ethyl
Maltol 10-80 parts.
4. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：- irisone 8-50 parts of 1-50 parts of (+)-limonene, γ, ethyl
Maltol 10-50 parts.
5. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：1 part of (+)-limonene, 8 parts of γ-irisone, ethylmaltol
15 parts.
6. application of the pharmaceutical composition as described in claim 1-5 in the medicine for preparing treatment atherosclerosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710070494.4A CN106902107A (en) | 2017-01-22 | 2017-01-22 | A kind of pharmaceutical composition for treating atherosclerosis and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710070494.4A CN106902107A (en) | 2017-01-22 | 2017-01-22 | A kind of pharmaceutical composition for treating atherosclerosis and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106902107A true CN106902107A (en) | 2017-06-30 |
Family
ID=59209196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710070494.4A Pending CN106902107A (en) | 2017-01-22 | 2017-01-22 | A kind of pharmaceutical composition for treating atherosclerosis and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106902107A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822070A (en) * | 2017-01-22 | 2017-06-13 | 新乡医学院 | A kind of pharmaceutical composition for treating atherosclerosis and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1258457A (en) * | 1998-08-07 | 2000-07-05 | Basf公司 | Application of cholesterol biosynthesis inhibitor for reducing cholesterol content of poultry eggs |
| CN100998414A (en) * | 2006-12-30 | 2007-07-18 | 云南工业大麻股份有限公司 | Application of powder of whole cannabis sativa seeds for preparing function food with adjuvant therapy of lowering blood fat |
-
2017
- 2017-01-22 CN CN201710070494.4A patent/CN106902107A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1258457A (en) * | 1998-08-07 | 2000-07-05 | Basf公司 | Application of cholesterol biosynthesis inhibitor for reducing cholesterol content of poultry eggs |
| CN100998414A (en) * | 2006-12-30 | 2007-07-18 | 云南工业大麻股份有限公司 | Application of powder of whole cannabis sativa seeds for preparing function food with adjuvant therapy of lowering blood fat |
Non-Patent Citations (1)
| Title |
|---|
| 靖丽: "柑橘精油的代谢图谱及其主要成分d-柠檬烯对糖脂代谢紊乱的防治作用研究", 《中国博士学位论文全文数据库，医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822070A (en) * | 2017-01-22 | 2017-06-13 | 新乡医学院 | A kind of pharmaceutical composition for treating atherosclerosis and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008536879A (en) | Drug or nutrition combination preparation and preparation, method for improving absorption by internal use, and application method thereof | |
| Unissa et al. | Thalassemia: a review | |
| CN106924226A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| CN107050005A (en) | A kind of pharmaceutical composition for treating atherosclerosis and its application | |
| CN106902107A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| CN104478832B (en) | Diterpene compound, containing its pharmaceutical composition and its preparation method and application | |
| CN105878221A (en) | Pharmaceutical composition for preventing atherosclerosis and application thereof | |
| CN106668050A (en) | Pharmaceutical composition for treating atherosclerosis and application of pharmaceutical composition | |
| CN106822067A (en) | Treat the application of the pharmaceutical composition and the pharmaceutical composition of atherosclerosis | |
| CN106074507A (en) | Pharmaceutical composition that prevention of arterial is atherosis and application thereof | |
| CN106913589A (en) | A kind of haematococcus pluvialis solid dispersions, Preparation Method And The Use | |
| CN106176766A (en) | One treats atherosclerotic pharmaceutical composition and application thereof | |
| CN104546822B (en) | The medical usage of epimedium aglucone | |
| CN107158008A (en) | A kind of pharmaceutical composition for treating myocardial infarction | |
| CN106822070A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| CN105998045A (en) | Pharmaceutical composition for treating atherosclerosis and application thereof | |
| CN106668051A (en) | Pharmaceutical composition for treating atherosclerosis and application thereof | |
| CN106822096A (en) | Treat the application of the pharmaceutical composition and the pharmaceutical composition of atherosclerosis | |
| CN106860439A (en) | Treat pharmaceutical composition and the application of atherosclerosis | |
| CN104083553B (en) | For preventing or treating the Chinese medicine extract of coronary heart disease, compositions and its production and use | |
| CN102429223A (en) | Health care food with assistant blood fat reducing function and preparation method thereof | |
| CN108743571A (en) | Prevent, treat the pharmaceutical composition and preparation method thereof of epilepsy | |
| CN106667977A (en) | Medicinal composition for treating atherosclerosis and application | |
| CN108434166A (en) | A kind of " Xuesaitong Injection " pharmaceutical composition and preparation method thereof, preparation and application | |
| CN106860472A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170630 |